Apheresis is a treatment modality by which blood is removed from and returned to the body on a continuous basis after filtering of the plasma (liquid portion) to remove deleterious cancer and inflammation promoting factors that contribute to disease progression. This unique approach was developed by Dr. Eliaz, and he is actively engaged in apheresis research with leading medical institutes. Currently, Dr. Eliaz is working with top experts in this field to develop specific filtering columns for advanced plasma filtration.
The device we currently use is an FDA approved system for removing elevated cholesterol in people with genetically-based elevations of low density lipoprotein (LDL) cholesterol. Many disease processes produce damaging oxidized fats and inflammatory compounds that result in unhealthy cell function. These are often found in high levels in our patients. Lowering these factors in conjunction with an individualized program that includes intravenous therapies and other treatments provides a novel and powerful therapeutic intervention with significant health benefits.
For cancer patients, this treatment when done at the right time has been shown to enhance chemotherapy and radiation effectiveness, reduce surgical inflammation, promote recovery, and reduce factors that contribute to disease progression. By dramatically reducing these deleterious compounds, apheresis lowers hyperviscosity and inflammation in the circulation and increases oxygenation, thereby reducing tumor-promoting signaling and allowing the immune system to function more optimally.
In a similar way, these treatments can also benefit patients with other chronic conditions such as Lyme disease and its co-infections, autoimmune conditions, cardiovascular disease, etc., as well as enhance the benefits of chelation and detoxification therapies.